Fuvestrol 250mg Injection

About

Fuvestrol 250mg Injection contains fulvestrant, an estrogen receptor antagonist that works by selectively binding to and degrading the estrogen receptor (ER) in breast cancer cells. Unlike selective estrogen receptor modulators (SERMs), fulvestrant is a pure anti-estrogen that causes downregulation of the ER protein, thereby inhibiting estrogen-dependent tumor growth. This mechanism makes it effective in hormone receptor-positive (HR+) metastatic breast cancer, particularly in postmenopausal women who have progressed on prior endocrine therapy. By reducing the number of functional estrogen receptors, fulvestrant effectively blocks the proliferative signals driven by estrogen, offering a crucial therapeutic option for patients with endocrine-sensitive tumors. Its unique mode of action, involving receptor degradation, distinguishes it from other endocrine therapies and provides a valuable strategy for overcoming resistance mechanisms.

Uses

• Treatment of hormone receptor-positive (HR+) metastatic breast cancer.
• Used in postmenopausal women.
• For patients with disease progression following endocrine therapy.
• Can be used in combination with CDK4/6 inhibitors.

Directions For Use

Administer as an intramuscular injection into the buttock. The injection should be given slowly.

Benefits

• Targets estrogen receptors directly.
• Effective in HR+ metastatic breast cancer.
• Pure anti-estrogen action.
• Can be used after other endocrine therapies fail.
• May improve progression-free survival.
• Well-established safety profile.

Side Effects

• Injection site pain
• Nausea
• Fatigue
• Headache
• Hot flashes
• Bone pain
• Arthralgia
• Vomiting
• Anorexia
• Peripheral edema
• Elevated liver enzymes
• Urinary tract infection

Safety Measures

• Alcohol - No specific contraindication with alcohol, but general health recommendations apply, especially during cancer treatment.
• Pregnancy - Fuvestrol is contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment with Fuvestrol and for a period after the last dose, as the drug may be excreted in breast milk.
• Liver - Use with caution in patients with moderate to severe hepatic impairment. Dose adjustments may be necessary.
• Kidney - No dose adjustment is generally required for mild to moderate renal impairment. Caution in severe impairment.
• Lung - No specific lung-related safety concerns are typically associated with fulvestrant.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.